Progenics Pharmaceuticals, Inc. (PGNX) - Financial and Strategic SWOT Analysis Review

Date: July 19, 2016
Pages: 53
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P777AF6C943EN
Leaflet:

Download PDF Leaflet

Progenics Pharmaceuticals, Inc. (PGNX) - Financial and Strategic SWOT Analysis Review
Progenics Pharmaceuticals, Inc. (PGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Progenics Pharmaceuticals, Inc. (Progenics) is a late-stage biopharmaceutical company that focuses on developing medicines and products for the treatment of cancer and related conditions. Its only commercial product, Relistor, is used for the treatment of opioid-induced constipation. The company’s pipeline comprises therapeutic agents that are designed to target cancer; PSMA-targeted imaging agents for prostate cancer that enable clinicians and patients to visualize and manage their disease; and a phase III candidate for the treatment of HIV. Progenics also offers bone scan index product, namely, EXINI Bone BSI tool which reads bone scans and produce automated bone scan index quantification. Its EXINI Bone BSI tool is approved for use in Europe, Japan and the US. Through a licensing agreement with Salix Pharmaceuticals the company markets Relistor outside the US except Japan. Progenics is headquartered in Tarrytown, New York, the US.

Progenics Pharmaceuticals, Inc. Key Recent Developments

Jun 13, 2016: Progenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016
Jun 09, 2016: Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
May 05, 2016: Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results
Mar 11, 2016: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results
Jan 07, 2016: Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

    Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

    Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

    Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

    Note: Some sections may be missing if data is unavailable for the company
  • SECTION 1 - ABOUT THE COMPANY

    Progenics Pharmaceuticals, Inc. - Key Facts
    Progenics Pharmaceuticals, Inc. - Key Employees
    Progenics Pharmaceuticals, Inc. - Key Employee Biographies
    Progenics Pharmaceuticals, Inc. - Major Products and Services
    Progenics Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data
    Progenics Pharmaceuticals, Inc., Pipeline Products by Therapy Area
    Progenics Pharmaceuticals, Inc., Pipeline Products by Development Phase
    Progenics Pharmaceuticals, Inc. - History
    Progenics Pharmaceuticals, Inc. - Company Statement
    Progenics Pharmaceuticals, Inc. - Locations And Subsidiaries
    Head Office
    Other Locations & Subsidiaries

    SECTION 2 – COMPANY ANALYSIS

    Progenics Pharmaceuticals, Inc. - Business Description
    Progenics Pharmaceuticals, Inc. - Corporate Strategy
    Progenics Pharmaceuticals, Inc. - SWOT Analysis
    SWOT Analysis - Overview
    Progenics Pharmaceuticals, Inc. - Strengths
    Strength - Research and Development Activities
    Strength - Lead Product - Relistor
    Progenics Pharmaceuticals, Inc. - Weaknesses
    Weakness - Declining Working Capital
    Progenics Pharmaceuticals, Inc. - Opportunities
    Opportunity - Market Potential – Oncology
    Opportunity - Pipeline Products
    Opportunity - Orphan Drug Designation
    Progenics Pharmaceuticals, Inc. - Threats
    Threat - Stringent Government Regulations
    Threat - Influx of Generics
    Threat - Lack of Manufacturing Facilities
    Progenics Pharmaceuticals, Inc. - Key Competitors

    SECTION 3 – COMPANY FINANCIAL RATIOS

    Financial Ratios - Capital Market Ratios
    Financial Ratios - Annual Ratios
    Performance Chart
    Financial Performance
    Financial Ratios - Ratio Charts

    SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

    Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Progenics Pharmaceuticals, Inc., Recent Deals Summary

    SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

    Jun 13, 2016: Progenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016
    Jun 09, 2016: Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
    May 05, 2016: Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results
    Mar 11, 2016: Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results
    Jan 07, 2016: Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer
    Nov 16, 2015: Progenics Pharmaceuticals Announces the Appointment of Patrick Fabbio as Chief Financial Officer
    Nov 09, 2015: Progenics Pharmaceuticals Announces Third Quarter 2015 Financial Results
    Oct 12, 2015: Data From Phase 2 Study of Progenics’ 1404 Imaging Agent Presented at EANM Congress 2015
    Aug 06, 2015: Progenics Pharmaceuticals Announces Second Quarter 2015 Financial Results
    May 06, 2015: Progenics Pharmaceuticals Announces First Quarter 2015 Financial Results

    SECTION 6 – APPENDIX

    Methodology
    Ratio Definitions
    About GlobalData
    Contact Us
    Disclaimer

    LIST OF TABLES

    Progenics Pharmaceuticals, Inc., Key Facts
    Progenics Pharmaceuticals, Inc., Key Employees
    Progenics Pharmaceuticals, Inc., Key Employee Biographies
    Progenics Pharmaceuticals, Inc., Major Products and Services
    Progenics Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area
    Progenics Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage
    Progenics Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase
    Progenics Pharmaceuticals, Inc., History
    Progenics Pharmaceuticals, Inc., Subsidiaries
    Progenics Pharmaceuticals, Inc., Key Competitors
    Progenics Pharmaceuticals, Inc., Ratios based on current share price
    Progenics Pharmaceuticals, Inc., Annual Ratios
    Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Progenics Pharmaceuticals, Inc., Recent Deals Summary
    Currency Codes
    Capital Market Ratios
    Equity Ratios
    Profitability Ratios
    Cost Ratios
    Liquidity Ratios
    Leverage Ratios
    Efficiency Ratios

    LIST OF FIGURES

    Progenics Pharmaceuticals, Inc., Pipeline Products by Therapy Area
    Progenics Pharmaceuticals, Inc., Pipeline Products by Development Phase
    Progenics Pharmaceuticals, Inc., Performance Chart (2011 - 2015)
    Progenics Pharmaceuticals, Inc., Ratio Charts
    Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
    Skip to top


    Ask Your Question

    Progenics Pharmaceuticals, Inc. (PGNX) - Financial and Strategic SWOT Analysis Review
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: